• Product name

    Anti-Met (c-Met) antibody [SP59]
    See all Met (c-Met) primary antibodies
  • Description

    Rabbit monoclonal [SP59] to Met (c-Met)
  • Host species

  • Tested applications

    Suitable for: IHC-Pmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Met (c-Met) aa 950-1050 (internal sequence). The exact sequence is proprietary. Corresponding to the region of Met (c-Met) that contains non-phosphorylated tyrosine1003.
    Database link: P08581

  • Positive control

    • Breast carcinoma



Our Abpromise guarantee covers the use of ab101539 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.


  • Function

    Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
  • Involvement in disease

    Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
    Note=Defects in MET may be associated with gastric cancer.
    Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
    Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
    Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
    Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 3 IPT/TIG domains.
    Contains 1 protein kinase domain.
    Contains 1 Sema domain.
  • Domain

    The kinase domain is involved in SPSB1 binding.
  • Post-translational

    Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • AUTS9 antibody
    • c met antibody
    • D249 antibody
    • Hepatocyte growth factor receptor antibody
    • HGF antibody
    • HGF receptor antibody
    • HGF/SF receptor antibody
    • HGFR antibody
    • MET antibody
    • Met proto oncogene antibody
    • Met proto oncogene tyrosine kinase antibody
    • MET proto oncogene, receptor tyrosine kinase antibody
    • Met proto-oncogene (hepatocyte growth factor receptor) antibody
    • Met proto-oncogene antibody
    • Met protooncogene antibody
    • MET_HUMAN antibody
    • Oncogene MET antibody
    • Par4 antibody
    • Proto-oncogene c-Met antibody
    • RCCP2 antibody
    • Scatter factor receptor antibody
    • SF receptor antibody
    • Tyrosine-protein kinase Met antibody
    see all


  • ab101539 at 1/100 dilution staining Met (C-Met) in Human breast carcinoma by Immunohistochemistry Formalin-fixed, Paraffin-embedded tissue.


ab101539 has not yet been referenced specifically in any publications.

Customer reviews and Q&As


We unfortunately do not have any data for mouse reactivity. I think it is very likely that the antibody will cross-react with mouse c-Met, given that the region the human immunogen is derived from is completely conserved in mouse c-Met. To identify the implanted cells, you may need to co-stain with an antibody that is known to be reactive with human, but non-reactive with mouse, such as the vimentin clone V9. The biotinylated version of this is ab79032:

Click here (or use the following: https://www.abcam.com/index.html?datasheet=79032).

The biotinylation will make the antibody easier to use on mouse tissue, since an unconjugated version will require an anti-mouse IgG secondary, which could react with endogenous mouse IgG in the liver. You will, however, require avidin or streptavidin conjugated to a fluorochrome or enzyme (e.g., HRP), depending on your detection method.

For a co-stain, you will also want an anti-rabbit IgG secondary antibody that is known to not react with mouse IgG. We have several to choose from. Please let me know if you want to pursue this. I will be happy to help.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up